Viva Biotech Revenues Surge on Move Into Contract Drug Manufacturing

Two key acquisitions last fall helped fuel fivefold rise in first-half revenue, as company swung back into profitability Key Takeaways: Viva Biotech’s fivefold jump in first-half revenues and move back to profitability come on the back of its acquisition last year of two contract drug makers Company’s shift to contract drug making comes as global pharma firms shift focus to drug development By Richard Barbarossa A couple of recent acquisitions are proving strong tonic for Viva Biotech Holdings (1873.HK), a globally-focused Chinese provider of third-party pharmaceutical services for other drug…

Read MORE »